No Data
Theratechnologies to Announce Third Quarter 2024 Financial Results and Provide Business Update
Theratechnologies Faces Potential Supply Disruption For Its Top Selling Drug, Warns of Revenue Impact Due To Manufacturing Delays
Theratechnologies Announces a Risk of a Temporary Supply Disruption for EGRIFTA SV in Early 2025
Theratechnologies to Present at Upcoming Investor Conferences in September
Positive Signs As Multiple Insiders Buy Theratechnologies Stock
Theratechnologies Second Quarter 2024 Earnings: Beats Expectations
No Data